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Introduction
I
ndividual susceptibility to infectious disease, such as
HIV-1, is strongly inﬂuenced by the genetic proﬁle of the
host. Allelic variants of the human major
histocompatibility complex (human leukocyte antigen [HLA])
genes have been implicated repeatedly with susceptibility,
course, and outcome of HIV-1 infection [1]. The HLA Class I
loci is genetically diverse, and in addition to its functions in
presenting peptide fragments of the invading pathogen to
CD8þ T cells, may assume other functions, such as direct
interaction with natural killer (NK) cells. Alleles of the Class I
A and B loci form the Bw4/Bw6 cluster, a grouping based on
an exposed epitope on the a1 helix, on the lip of the peptide
binding cleft. This region of the HLA molecule is known to
interact with NK cells via the killer Ig-like receptor (KIR).
Expressed on the NK cell surface, KIR is allelic, with forms
that, upon engagement with an HLA Class I ligand, may
either inhibit or activate an NK cell. The KIR receptor alleles
fall into two broad groups: forms with a long cytoplasmic tail
(such as KIR2DL1) bear an immune tyrosine inhibitory motif
and inhibit, while the short-tail forms (such as KIR2DS2)
activate NK cells [2]. Upon engagement with an HLA Class I
ligand, short-tail forms of KIR may increase NK cell effector
activity, inducing the release of perforin and granzyme, and
secretion of IFN-c [2] .
Summary of Observational Studies on HLA and KIR
on HIV-1 Disease Progression
Flores-Villanueva and colleagues noted that HIV-1-infected
persons with superior control of viral replication in the
absence of anti-retroviral treatment were more likely to be
homozygous for a Bw4 allele than those who could not control
infection [3]. The Bw4 cluster, in addition to bearing an
epitope that interacts with certain KIRs, contains a number
of HLA types known to confer protection against HIV-1
disease progression, such as B*57 and B*27. The Bw4 cluster
does not contain the B*35 allele, of which the B*35Px variant
[4] has been linked to accelerated disease progression. Hence,
the association of Bw4 with improved outcomes may be
linked to the inclusion of strongly protective alleles such as
B*57, the exclusion of others such as B*35, and or interaction
with a form of KIR.
The Bw4 epitope contains a subset of alleles known as
Bw4Ile80, which bear an isoleucine in position 80 of the a1
helix, the lip of the HLA binding cleft. The Bw4Ile80 epitope
may be important in T cell modulation [5] and
immunomodulation of NK cell function [6]. The Bw4Ile80
epitope interacts with the KIR3DL1 inhibitory allele.
KIR3DS1 is a short-tailed form of KIR, and has very high
sequence homology to KIR3DL1 in its extracellular domains.
KIR3DS1 was predicted to likewise interact with Bw4Ile80
molecules, although this interaction had not been directly
observed. Martin et al. examined the epistatic interaction of
KIR3DS1 and Bw4Ile80 for the effect on time to the onset of
AIDS [7] in a cohort of HIV-1-infected adults in North
America. They observed that Bw4Ile80/KIR3DS1 carriers
experienced a signiﬁcant delay in time to disease. The authors
controlled their analysis for the known effects of the
protective B*27, B*57, and the deleterious B*35 alleles. Hence,
the Bw4Ile80/KIR3DS1 effect on disease progression may be
due to a synergistic beneﬁt of carriage of both the Bw4Ile80
and KIR3DS1 alleles, an effect which may be attributable to
enhanced NK cell activity via KIR activation [2].
In a subsequent study by Qi et al. [8] based on same cohorts
of HIV-1-infected persons studied by Martin et al., Bw4Ile80/
KIR3DS1 was associated with a delayed risk of development of
certain opportunistic infections. Qi et al. observed that
Bw4Ile80/KIR3DS1 carriers had an average HIV-1 RNA level
of 4.75 log10 copies/mL versus a viral load of 4.89 log10 copies/
mL for those who did not carry both genes, and suggested this
difference might at least partially explain the observed
clinical beneﬁts. This difference in viral replication is modest,
and may not be sufﬁcient to explain the beneﬁt in long-term
clinical outcome in HIV-1 disease that was observed among
persons with Bw4Ile80/KIR3DS1.
Gaudieri et al. examined HLA and KIR effects in a cohort
of HIV-1-infected persons in Australia [9]. The authors
observed an increased relative rate of CD4þ T cell percent
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Martin et al., Gaudieri et al. did not ﬁnd a signiﬁcant
protective effect against CD4þ T cell loss among Bw4Ile80/
KIR3DS1 carriers, and in fact found these persons were at
increased hazard (relative hazard of 14) for reaching AIDS
(under the 1987 US Centers for Disease Control and
Prevention deﬁnition).
In our contemporary cohort of recently HIV-1-infected
persons, we had the opportunity to observe the association of
Bw4Ile80 and KIR3DS1 alleles on HIV-1 RNA and CD4þT cell
levels during very early infection (see Protocol S1). These
individuals were treatment-naı ¨ve adults with precisely known
dates of seroconversion (within six months of seroconversion
for 90% of cases). Of the 255 persons in this analysis, the
median HIV-1 RNA level at study entry was 4.66 (interquartile
range [IQR] 3.77, 5.29) log10 HIV-1 RNA copies/mL, and the
median CD4þ T cell count was 534 (IQR 410, 674) cells/uL.
These persons were observed for a total of 263.7 person-years
prior to initiating potent anti-retroviral therapy. The study
population was 88% Caucasian and 94% were male,
reﬂecting the HIV-1 epidemic in San Francisco, where we are
based. Of these 255 individuals, 94 (37%) carried at least one
KIR3DS1 allele, 239 (94%) carried at least one KIR3DL1 allele,
114 (45%) carried at least one HLA Class I B Bw4Ile80 allele,
and 43 (17%) carried both a KIR3DS1 and an HLA-B Bw4Ile80
allele. We considered only HLA Class I B alleles as part of the
Bw4Ile80 cluster for this analysis.
With the beneﬁt of multiple HIV-1 RNA and CD4þ T cell
measures from very early in infection, we observed that the
KIR3DS1-bearing individuals had higher CD4þ T cell counts
during early infection (average þ 58 cells/uL [standard error
(SE)¼28.5] higher over time, p¼0.04, Figure 1A), but did not
have lower HIV-1 RNA levels ( 0.11 [SE ¼ 0.12] log10 copies/
mL, p ¼ 0.34, Figure 1A). In contrast, those carrying the
Bw4Ile80 allele had a signiﬁcant reduction in viral load at
study entry ( 0.37 log10 [SE ¼ 0.10] copies/mL, p ¼ 0.0003,
Figure 1B), but did not display a signiﬁcant difference in
CD4þ T cell counts ( 1.5 [SE ¼ 25.5] cells/uL, p ¼ 0.95, Figure
1B). Those carrying both Bw4Ile80 and KIR3DS1 did not
display a signiﬁcant trend towards higher CD4þT cell counts
over the period of observation (þ 40 cells/uL [SE ¼ 36.5], p ¼
0.27, Figure 1C), and displayed a trend towards a reduction in doi:10.1371/journal.ppat.0030043.g001
Figure 1. Effects of Bw4Ile80 and KIR3DS1 Gene Carriage on HIV Disease
Outcome
(A) Those with KIR3DS1 (dashed line) versus those without KIR3DS1. The
dashed red line represents a moving average of HIV-1 RNA levels over
time among those carrying at least one KIR3DS1 allele. The solid red line
represents those that do not carry the KIR3DS1 allele. The dashed blue
line represents a moving average of CD4þT cell counts over time among
those carrying at least one KIR3DS1 allele. The solid blue line represents
those that do not carry the KIR3DS1 allele.
(B) Those with Bw4Ile80 (dashed line) versus those without Bw4Ile80. The
dashed red line represents a moving average of HIV-1 RNA levels over
time among those carrying at least one Bw4Ile80 allele. The solid red line
represents those that do not carry the Bw4Ile80 allele. The dashed blue
line represents a moving average of CD4þT cell counts over time among
those carrying at least one Bw4Ile80 allele. The solid blue line represents
those that do not carry the Bw4Ile80 allele.
(C) Those with both the Bw4Ile80 and KIR3DS1 alleles (dashed line) versus
those without both alleles. The dashed red line represents a moving
average of HIV-1 RNA levels over time among those carrying both the
Bw4Ile80 and KIR3DS1 alleles. The solid red line represents those that do
not carry both the Bw4Ile80 and KIR3DS1 alleles. The dashed blue line
represents a moving average of CD4þ T cell counts over time among
those carrying at both the Bw4Ile80 and KIR3DS1 alleles. The solid blue
line represents those that do not carry both the Bw4Ile80 and KIR3DS1
alleles.
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mL, p ¼ 0.14, Figure 1C) relative to those who did not carry
both genes.
The reduction in viral load among Bw4Ile80/KIR3DS1
carriers was smaller ( 0.22 log10 [SE¼0.15] copies/ml, p¼0.14;
Figure 1C) than that reduction seen for all Bw4Ile80 ( 0.37
log10 copies/mL, p ¼ 0.0003, Figure 1B). And, the effect on
CD4þT cell count was smaller and not statistically signiﬁcant
for Bw4Ile80/KIR3DS1 compared to the effect for KIR3DS1
alone (þ40 cells/uL versusþ58 cells/uL, Figure 1C versus 1A).
That neither the viral load nor CD4þ T cell effects were
augmented among carriers of Bw4Ile80/KIR3DS1 suggests that
Bw4Ile80 and KIR3DS1 do not synergize to confer greater
protective effects on HIV-1 disease markers in early infection,
a period in which innate immunity ought to be active.
To further explore the possibility of synergy between
Bw4Ile80 and KIR3DS1, we compared those with KIR3DS1 and
lacking Bw4Ile80 to those who carried both genes. If Bw4Ile80
and KIR3DS1 were operating synergistically, we would expect
to see a greater beneﬁt on HIV-1 RNA levels, or CD4þ T cell
counts, among Bw4Ile80/KIR3DS1 versus those carrying
KIR3DS1 alone. The Bw4Ile80/KIR3DS1 carriers did not
display a trend towards higher CD4þ T cell counts ( 0.10 [SE
¼ 48.3] cells/uL over time, p ¼ 0.9) versus those who carried
KIR3DS1 alone. Those with both Bw4Ile80 and KIR3DS1
demonstrated a marginally signiﬁcant trend towards viral
load reductions ( 0.29 [SE ¼ 0.19] log10 copies/mL, p ¼ 0.12)
versus those who carried KIR3DS1 alone. This magnitude of
difference in viral load was similar to the deﬁcit observed
between those who did and did not carry Bw4Ile80 (Figure
1B), regardless of KIR3DS1 carriage (which was  0.37 log10
copies/mL, Figure 1B). This suggests that the effect on viral
load reduction was due to the Bw4Ile80 gene itself, and not
due to an interaction with KIR3DS1. Indeed, when persons
bearing B*57 (a Bw4Ile80 allele known to confer lower viral
loads) were removed from the analysis, the magnitude of the
viral load reduction was reduced from  0.37 log10 copies/mL
to 0.25 (SE¼0.10) log10 copies/mL, p¼0.02). The HLA B*57
allele, which is known to associate with very low viral loads
during early infection, may confer a large share of the viral
load reduction among Bw4Ile80 carriers, regardless of
KIR3DS1 carriage. Taken together, these data suggest that
KIR3DS1 may associate with elevated CD4þ T cell counts
during early infection in a manner independent of viral load,
with Bw4Ile80 having a modest additive beneﬁt via a small
reduction in HIV-1 RNA levels.
The reduction in viral load that we observed for the
Bw4Ile80/KIR3DS1 group was slightly larger than that
observed by Qi et al. ( 0.14 log10 c/ml for Qi et al. versus our
observation of  0.22 log10 c/mL). This magnitude of
difference in HIV-1 RNA levels observed by Bw4Ile80/
KIR3DS1 is small and may not be sufﬁcient to explain
differences in CD4þ T cell levels. Our results indicate that
there is an effect of KIR3DS1 carriage on CD4þT cell counts
independent of Bw4Ile80 carriage in early HIV-1 infection.
Bw4Ile80/KIR3DS1 joint carriage was associated with a modest
reduction in HIV-1 RNA levels, which is likely due to
independent activity of Bw4Ile80 member alleles, such as
B*57. The effect of KIR3DS1 on CD4þ T cell counts during
early infection may reﬂect higher CD4þT cell counts prior to
acquisition of infection, a sparing of CD4þ T cells during
early infection, or both.
We performed our analyses considering only HLA Class I B
loci alleles as part of the Bw4Ile80 cluster. This is consistent
with the approach by Martin et al. [7] and facilitates
comparison of results. When we included HLA Class I A loci
alleles as part of the Bw4Ile80 cluster, our main inference—
the absence of synergy between Bw4Ile80 and KIR3DS1 on
either viral load or CD4þ T cell count—was unchanged.
Until recently, it has not been clear whether HLA Class I A
loci alleles, which bear a Bw4Ile80 motif, interact with KIR
alleles, such as KIR3DL1. Recent work has suggested that
certain HLA Class I A Bw4Ile80 alleles, such as A*24, interact
with differing KIR3DL1 allotypes [10]. Binding of A*2402 to
certain allotypes was inﬂuenced by the nature of the peptide
bound. HIV-1 Nef and p17 peptides were observed to
enhance A*2402 binding to certain KIR3DL1 allotypes.
Hence, sequence of the acquired viral strain, and peptide
presentation patterns within the infected person, may
inﬂuence the interaction of HLA and KIR molecules.
Recent experimental results may shed light on the question
of Bw4 and KIR3DS1 interaction. O’Connor et al. recently
veriﬁed that KIR3DS1 is in fact expressed on the NK cell
surface, and was higher among homozgyotes than
heterozygotes. However, Carr et al. [11] and O’Connor et al.
[12] each separately demonstrated that neither Bw4 nor Bw6
ligands recognize KIR3DS1 extracellular domains. KIR3DS1
extracellular domains bear high sequence homology to
KIR3DL1 and were predicted to be recognized by Bw4 and
Bw4Ile80 molecules. That it was not recognized may indicate
that Bw4Ile80 molecules do not, as a group, recognize
KIR3DS1. Alternatively, and as the authors suggest, it is
possible that KIR allotype recognition by a Class I A or B
Bw4Ile80 molecule is dependent on the peptide bound in the
HLA cleft [10]. But, that has yet to be shown for KIR3DS1.
Our study focused on correlates of HIV-1 RNA and CD4þT
cell levels in the earliest stages of HIV-1 infection. Disease
progression rates are established in early infection [13,14],
and innate immune activity such as NK cell activity ought to
be present in the earliest stages of infection. An NK cell–
mediated effect on disease parameters such as CD4þ T cell
counts or viral load is likely to be observed at that time. The
study by Martin et al. noted that the effect of Bw4Ile80/
KIR3DS1 carriage on disease outcome (the fraction
remaining AIDS-free) was not present until year three of
infection. A deﬁnition of clinical AIDS is reached at a time of
severe CD4þ T cell loss late in infection. Hence, there may
have been an observable effect on CD4þT cell count and rate
of loss or on elevated and increasing HIV-1 RNA levels during
earlier time periods in the Martin et al. cohort.
The studies by Martin et al. and Qi et al. take a survival
analysis or time-to-event approach to an historical cohort
with extended pre-treatment follow-up. This approach to
observational data does not make use of all available clinical
data. In our cohort, we used longitudinal mixed effects
modeling statistics (as did Gaudieri et al.) that allowed us to
make use of all of our data over time. Our cohort has the
advantage of being contemporary (enrollment 1996 to
present) and having tightly spaced HIV-1 RNA and CD4þ T
cell measurements during early infection. Our study is larger
in enrollment than that by Gaudieri et al., and has more
precisely known dates for seroconversion. However, our
cohort, as it has been under observation since the advent of
effective anti-retroviral therapy, has less untreated follow-up
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extend to the effect of Bw4Ile80 and KIR3DS1 carriage
beyond the ﬁrst two years of HIV-1 infection.
Neither our study nor others described here have
addressed the issue of KIR ‘‘dose’’ or expression patterns
beyond whether an individual is an homozygotic or
heterozygotic carrier of an allele. That is, individuals carry
variable numbers of KIR genes (six to 19 genes) [2], which can
lead to complex expression patterns. The number and
pattern of KIR3DS1 or other activating alleles carried by an
individual may have an impact on the clinical phenotypes
described here, and may help explain the discrepancy in
outcomes across studies.
Alternative explanations for a role of KIR3DS1 in delayed
disease progression may exist. KIR molecules may be found
on cell types other than NK cells. For example, KIR2DS2
molecules are expressed on T cells [15] among those suffering
from chronic inﬂammatory conditions such as rheumatoid
arthritis [16], and may inﬂuence the activation state and
cytokine expression of these T cell populations. Snyder et al.
observed that, upon antibody stimulation of surface KIR2DS2
on CD4þ CD28
null DAP12–expressing T cells, the signaling
protein Erk was phosphorylated and IFN-c production
increased [17]. In this way, KIR-activating alleles, of which
KIR3DS1 is a member, may inﬂuence CD4þ and/or CD8þ T
cell activation states in a manner independent of T cell
receptor stimulation. Hence, it is possible the KIR3DS1
expression on lymphocytes inﬂuences the activity and
activation state of memory CD4þ T cells in HIV disease and,
in turn, inﬂuences bystander cell death or dysfunction of
uninfected CD4þ T cells [18]. Again, the ligand for such an
effect is not known.
While our data do not support an interaction for Bw4Ile80
and KIR3DS1, it remains possible that there is an interaction
which manifests later in disease, dependent on an unknown
ligand or on presentation of speciﬁc HIV-1 peptide
fragments that are not processed until later in infection.
Alternatively, KIR3DS1 expression alone may confer a
protective effect on CD4þ T cell counts in HIV-1 disease
absent interaction with a Bw4 ligand via direct modulation of
CD4þ or CD8þ T cells that express KIR [17]. Further
experimental work is needed to verify the regulation,
expression, and localization of KIR3DS1, its interaction with
Class I ligands, and dependence on the peptide fragment
bound by a Class I molecule. &
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